Publications
Publications
Jun, 2025
We are excited to share that our latest manuscript, "Real-world outcomes of
duvelisib and romidepsin combination therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL)," has been accepted for publication in
Blood Advances. Read more on how it offers critical real-world evidence supporting a promising treatment strategy to improve outcomes and
facilitate curative transplants for patients with aggressive PTCL.
We are excited to share that our latest
manuscript, "Real-world outcomes
of duvelisib and romidepsin combination
therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL),"
has been accepted for publication in
Blood Advances. Read more on how it
offers critical real-world
evidence supporting a promising
treatment strategy to improve
outcomes and facilitate curative
transplants for patients with
aggressive PTCL.
We are excited to share that our latest manuscript, "Real-world outcomes of
duvelisib and romidepsin combination therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL)," has been accepted for publication in
Blood Advances. Read more on how it offers critical real-world evidence supporting a promising treatment strategy to improve outcomes and
facilitate curative transplants for patients with aggressive PTCL.
May, 2025
We are excited to announce that our paper, Forecasting optimal treatments
in relapsed/refractory mature T- and NK-cell lymphomas, has been
published in the British Journal of Haematology. This collaborative work
leverages machine learning and genomic insights to predict the most
effective treatment regimens for aggressive T- and NK-cell lymphomas.
We are excited to announce that
our paper, Forecasting optimal treatments
in relapsed/refractory mature T-
and NK-cell lymphomas, has been
published in the British Journal of
Haematology. This collaborative work
leverages machine learning and genomic
insights to predict the most
effective treatment regimens for
aggressive T- and NK-cell lymphomas.
We are excited to announce that our paper, Forecasting optimal treatments
in relapsed/refractory mature T- and NK-cell lymphomas, has been
published in the British Journal of Haematology. This collaborative work
leverages machine learning and genomic insights to predict the most
effective treatment regimens for aggressive T- and NK-cell lymphomas.
March 2025
T-cell Lymphoma Forum (TCLF) 2025
The PETAL Consortium and Jain Lab T-cell lymphoma program was invited to give 3 oral presentations and 2 poster presentation on their latest ongoing work on the global PETAL consortium - an incorporation of novel machine learning strategies to estimate patient outcomes for peripheral T-cell lymphoma.
February, 2025
Our paper Global outcomes and prognosis for relapsed/refractory
mature T-cell and NK-cell lymphomas: results from the PETAL consortium
gets highlighted on Blood Advances Today.
Our paper Global outcomes and
prognosis for relapsed/refractory
mature T-cell and
NK-cell lymphomas: results
from the PETAL consortium gets
highlighted on Blood Advances Today.
Our paper Global outcomes and prognosis for relapsed/refractory
mature T-cell and NK-cell lymphomas: results from the PETAL consortium
gets highlighted on Blood Advances Today.
We are excited to share this editorial on our Blood Advances
paper PETAL: a global view on R/R T/NK-lymphoma
treatment reality.
We are excited to share this
editorial on our Blood Advances
paper PETAL: a global view
on R/R T/NK-lymphoma
treatment reality.
We are excited to share this editorial on our Blood Advances
paper PETAL: a global view on R/R T/NK-lymphoma
treatment reality.
December 2024
American Society of Haematology Conference 2024
The Jain Lab T Cell Lymphoma program was invited to give an oral presentation on the PETAL Consortium’s novel PIRT scoring tool. In addition, three poster presentations were given and are listed below. We are extremely excited for our team and their wonderful accomplishments!
October, 2024
Another great milestone achieved for PETAL as our paper, “Global Outcomes and Prognosis for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas: Results from the PETAL Consortium,” has been accepted for publication in Blood Advances, the open-access journal of the American Society of Hematology.
Another great milestone achieved
for PETAL as our paper,
“Global Outcomes and Prognosis
for Relapsed/Refractory Mature
T-Cell and NK-Cell Lymphomas:
Results from the PETAL
Consortium,”
has been accepted for publication
in Blood Advances, the
open-access journal of the
American Society of Hematology.
Another great milestone achieved for PETAL as our paper, “Global Outcomes and
Prognosis for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas:
Results from the PETAL Consortium,” has been accepted for publication in Blood
Advances, the open-access journal of the American Society of Hematology.
July, 2024
Congratulations to Makoto Iwasaki, MD, PhD, on receiving the esteemed ASH Global Research Award from the American Society of Hematology (ASH) with the support of Caroline MacVicar! This award will support his research in developing machine learning models to predict T-cell lymphoma outcomes.
Congratulations to Makoto Iwasaki,
MD, PhD, on receiving
the esteemed ASH Global
Research Award from the
American Society of Hematology (ASH)
with the support of Caroline
MacVicar! This award will support
his research in developing
machine learning models to
predict T-cell lymphoma outcomes.
Congratulations to Makoto Iwasaki, MD, PhD, on receiving the esteemed ASH
Global Research Award from the American Society of Hematology (ASH) with
the support of Caroline MacVicar! This award will support his research in
developing machine learning models to predict T-cell lymphoma outcomes.
Makoto Iwasaki
Congratulations to Shambhavi Singh, MD, PhD, for being selected as a recipient of the 2024 ASH Hematology Opportunities for the Next-Generation of Research Scientists (HONORS) Award.
Congratulations to Shambhavi Singh,
MD, PhD, for being selected
as a recipient of the
2024 ASH Hematology Opportunities
for the Next-Generation of
Research Scientists (HONORS) Award.
Congratulations to Shambhavi Singh, MD, PhD, for being selected as a
recipient of the 2024 ASH Hematology Opportunities for the Next-Generation
of Research Scientists (HONORS) Award.
Shambhavi Singh
@2025 PETAL Consortium • All rights reserved
@2025 PETAL Consortium • All rights reserved
@2025 PETAL Consortium • All rights reserved